A
10.97
-0.52 (-4.53%)
| 前收盘价格 | 11.49 |
| 收盘价格 | 11.49 |
| 成交量 | 1,625,331 |
| 平均成交量 (3个月) | 1,929,313 |
| 市值 | 1,084,369,280 |
| 价格/销量 (P/S) | 8.26 |
| 股市价格/股市净资产 (P/B) | 7.62 |
| 52周波幅 | |
| 利润日期 | 10 Nov 2025 |
| 营业毛利率 | -16.11% |
| 营业利益率 (TTM) | -466.29% |
| 稀释每股收益 (EPS TTM) | -0.160 |
| 季度收入增长率 (YOY) | 4,900.00% |
| 总债务/股东权益 (D/E MRQ) | 30.33% |
| 流动比率 (MRQ) | 11.00 |
| 营业现金流 (OCF TTM) | -20.48 M |
| 杠杆自由现金流 (LFCF TTM) | -9.60 M |
| 资产报酬率 (ROA TTM) | -6.10% |
| 股东权益报酬率 (ROE TTM) | -6.91% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | ARS Pharmaceuticals, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
-0.1
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | -0.13 |
|
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 16.93% |
| 机构持股比例 | 80.28% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Casdin Capital, Llc | 30 Sep 2025 | 1,600,000 |
| Southpoint Capital Advisors Lp | 30 Sep 2025 | 1,500,000 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合